Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization…
Browsing: HealthCare
Hua Medicine (the Company, HKG: 2552) announced today that the Company has successfully completed a Phase I clinical trial on…
Hua Medicine (the Company, HKG: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism…
Significantly Boosting Market Penetration and Driving Valuation Reassessment On November 28, the National Healthcare Security Administration (NHSA) and the Ministry…
Starting A New Chapter in Healthcare Industry Development Kingworld Medicines Group Limited (Kingworld Medicines or the Group, HKG: 1110), a…
Fosun’s creditworthiness has notably improved and gained market recognition On 21 November 2024, S&P Global Ratings released an updated report…
– Net Profit Surges 53.4% to HK$95.9 Million – Interim Dividend of HK5.50 cents per share, up by 59.4% year-on-year…
Marking Another Milestone in Commercialization Today, Everest Medicines announced that NEFECON(R) has received full approval from the Ministry of Food…
Despite Singapore’s abundant sunlight, Vitamin D deficiency remains a prevalent health issue, affecting millions of people. This deficiency significantly compromises bone…
– Anticipates Not Less Than 50% Rise in Consolidated Profit Attributable to Shareholders JBM (Healthcare) Limited (JBM Healthcare or the…
Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on…
Public Offering of 54.22 Million Issue Shares for Listing on the ACE Market of Bursa Malaysia TOPVISION Eye Specialist Berhad (“TOPVISION”…
– Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients Everest Medicines (HKG: 1952, Everest, or the…
The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li,…
– Demonstrating Benefits of Berberine Ursodeoxycholate (HTD1801) HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the…
HK equity market experienced snap adjustment rally in September, and is now entering stock picking phase before new round of…
Empowering Women and Their Health in the Workplace at GJK Facility Services In recognition of Breast Cancer Awareness Week, George…
Enhancing the Quality of Life for All, Commiting to Investing in Technology Upgrades, and Developing Pharmaceutical and Healthcare Product Innovations…
– Published in “Kidney 360” Magazine Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the…
– ACROMETA seeks to unlock value from its disposal of Life Science Incubator Holdings Pte. Ltd. following a strategic review.…